Cycle Pharmaceuticals Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Approved
Nrf2 pathway (fumaric acid ester)Small molecule
Multiple Sclerosis
Approved
S1P receptorSmall molecule
Multiple Sclerosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.